ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

avatrombopag

Also written as “E5501”, “Avatrombopag” and “Avatrombopag 20 mg Oral Tablet”.

Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Thrombocytopenia · Anemia, Aplastic, led by 2 companies.

Drug pageAvatrombopag: every studyAll 52 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 13, 201125 company-led studies, 1 open or runningNext primary completion: Jun 30, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eisaiits history only180 open or runningphase 3since Sep 13, 2011Feb 27, 2007none ahead
Swedish Orphan Biovitrum71 open or runningphase 4since Nov 11, 2020Oct 27, 2017Jun 30, 2028phase 3 · NCT07786922

Also a collaborator on its studies: CMIC Co, Ltd. Japan.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Swedish Orphan Biovitrum only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 27, 2017First study: phase 3 study in ThrombocytopeniaFirst studyNCT03326843 · 4 enrolled · United States
  2. Mar 7, 2018Phase 3 study in ThrombocytopeniaNCT03471078 · 122 enrolled · United States, China, Hungary and more
  3. Aug 14, 2020Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT04516967 · 75 enrolled · United States, France, Germany and more
  4. Nov 11, 2020Phase 4 study in Purpura, Thrombocytopenic, IdiopathicNCT04638829 · 60 enrolled · United States
  5. Sep 8, 2021Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT05046327
  6. Apr 21, 2022Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT05369208 · 19 enrolled · Japan
  7. Jul 30, 2026Phase 3 study in Anemia, AplasticNCT07786922 · 26 planned

Ahead

  1. Jun 30, 2028Primary completion: phase 3 study in Anemia, AplasticNCT07786922

TargetBeta

MPL →read by rule
“The maleate salt form of avatrombopag, an orally available platelet thrombopoietin receptor (TPOR; MPL) agonist, ”NCIt, by rule
“Thrombopoietin receptor agonist; Thrombopoietin receptor agonist”ChEMBL 37, by rule

Other programs on MPL

ProgramCompanyFurthest phaseStudies
eltrombopagruleGlaxoSmithKlinephase 449
romiplostimruleAmgenphase 438
hetrombopag olamineruleJiangsu HengRui Medicinephase 315

Studies

All 7 Swedish Orphan Biovitrum leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07786922Anemia, Aplastic3Not yet recruitingJun 30, 202826
NCT05369208Purpura, Thrombocytopenic, Idiopathic · Japan3CompletedJan 17, 202419
NCT05046327Purpura, Thrombocytopenic, Idiopathic3WithdrawnApr 6, 20240
NCT04638829Purpura, Thrombocytopenic, Idiopathic · United States4CompletedJan 3, 202460
NCT04516967Purpura, Thrombocytopenic, Idiopathic · United States, France, Germany and more3CompletedNov 8, 202375
NCT03471078Thrombocytopenia · United States, China, Hungary and more3CompletedAug 28, 2020122
NCT03326843Thrombocytopenia · United States3TerminatedFeb 25, 20194

How it is read

Names in the registry

  • “E5501”, 9 entries
  • “Avatrombopag”, 8 entries
  • “Avatrombopag 20 mg Oral Tablet”, 2 entries
  • “Avatrombopag Oral Tablet”, 2 entries
  • “avatrombopag”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.